Examkin

Question

Difficulty: EasyRheumatology and Immunology

A 45-year-old woman is newly diagnosed with seropositive rheumatoid arthritis involving her metacarpophalangeal and proximal interphalangeal joints. According to standard clinical guidelines, arrange the following therapeutic interventions in the correct chronological sequence of escalation, starting from the initial medical management to the treatment of advanced, medically refractory disease.

  1. 1Initiation of a conventional synthetic DMARD (e.g., methotrexate)
  2. 2Addition of a biologic TNF inhibitor (e.g., adalimumab)
  3. 3Transitioning to a non-TNF biologic agent (e.g., rituximab)
  4. 4Referral for surgical joint reconstruction

Answer

The correct sequence of therapy escalation for rheumatoid arthritis is: 1) Initiation of a conventional synthetic DMARD (methotrexate), 2) Addition of a biologic TNF inhibitor, 3) Transitioning to a non-TNF biologic agent, and 4) Referral for surgical joint reconstruction.
The standard paradigm for rheumatoid arthritis management follows a defined step-up approach. Treatment invariably begins with a conventional synthetic DMARD, almost exclusively methotrexate, which serves as the anchor drug. If the disease remains active after 3 to 6 months of optimized methotrexate, a biologic DMARD (usually a TNF inhibitor) is added to the regimen. If the patient has an inadequate response to the first biologic, guidelines suggest switching to a biologic with a different mechanism of action, such as a CD20 monoclonal antibody (rituximab) or an IL-6 inhibitor (tocilizumab). Finally, if all medical therapy fails and the patient develops end-stage structural joint destruction with intractable pain, surgical options such as arthroplasty or arthrodesis are pursued.

Step-by-Step Solution

1
Determine the initial first-line therapy for newly diagnosed rheumatoid arthritis.
Initiation of a conventional synthetic DMARD (e.g., methotrexate).
Guidelines universally recommend starting with a conventional synthetic DMARD as the foundational step to modify disease progression.
2
Identify the standard step-up management if initial therapy fails to control disease activity.
Addition of a biologic TNF inhibitor (e.g., adalimumab).
Combining a conventional DMARD with a biologic agent, typically a TNF inhibitor, is the standard secondary escalation step.
3
Determine the subsequent pharmacological step if the first biologic DMARD is ineffective.
Transitioning to a non-TNF biologic agent (e.g., rituximab).
If one mechanism (TNF inhibition) fails, switching to a biologic targeting a different pathway (e.g., CD20, IL-6) is indicated.
4
Identify the management for end-stage structural damage that no longer responds to medications.
Referral for surgical joint reconstruction.
Pharmacotherapy cannot reverse advanced structural damage; surgery is the final intervention for functional restoration.

Key Concept

Step-up pharmacotherapy escalation in rheumatoid arthritis
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic